ITGA3 promotes pancreatic cancer progression through HIF1α- and c-Myc-driven glycolysis in a collagen I-dependent autocrine manner
- PMID: 39690180
- DOI: 10.1038/s41417-024-00864-7
ITGA3 promotes pancreatic cancer progression through HIF1α- and c-Myc-driven glycolysis in a collagen I-dependent autocrine manner
Abstract
Pancreatic cancer is characterized by severe metabolic stress due to its prominent desmoplasia and poor vascularization. Integrin subunit alpha 3 (ITGA3) is a cell surface adhesion protein involved in tumor progression. However, the role of ITGA3 in pancreatic cancer progression, especially in metabolic reprogramming, remains largely unknown. In this study, we found that ITGA3 expression is elevated in pancreatic cancer tissues and predicts poor prognosis for patients with pancreatic cancer. Functional assays revealed that ITGA3 promotes the growth and liver metastasis of pancreatic cancer via boosting glycolysis. Mechanistically, Collagen I (Col1) derived from cancer cells acts as a ligand for ITGA3 to activate the FAK/PI3K/AKT/mTOR signaling pathway in an autocrine manner, thereby increasing the expression of HIF1α and c-Myc, two critical regulators of glycolysis. Blockade of Col1 by siRNA or of ITGA3 by a blocking antibody leads to specific inactivation of the FAK/PI3K/AKT/mTOR pathway and impairs malignant tumor behaviors induced by ITGA3. Thus, our data indicate that ITGA3 enhances glycolysis to promote pancreatic cancer growth and metastasis via increasing HIF1α and c-Myc expression in a Col1-dependent autocrine manner, making ITGA3 as a candidate diagnostic biomarker and a potential therapeutic target for pancreatic cancer.
© 2024. The Author(s), under exclusive licence to Springer Nature America, Inc.
Conflict of interest statement
Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: The use of human pancreatic cancer specimens was approved by the Research Ethics Committee of Renji Hospital (Ethics No. RA-2017-096). Informed consent was obtained from all subjects involved in the study. The human specimens were de-identified and all methods using the human specimens in this study were performed in accordance with the relevant guidelines and regulations. All animal experiments were approved by the Jiangsu University Animal Ethics and Experimentation Committee (License: SYXK (S) 2018-0053).
Similar articles
-
ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.Gastroenterology. 2020 Feb;158(3):679-692.e1. doi: 10.1053/j.gastro.2019.10.038. Epub 2019 Nov 9. Gastroenterology. 2020. PMID: 31711924 Free PMC article.
-
ITGA3-MET interaction promotes papillary thyroid cancer progression via ERK and PI3K/AKT pathways.Ann Med. 2025 Dec;57(1):2483379. doi: 10.1080/07853890.2025.2483379. Epub 2025 Mar 26. Ann Med. 2025. PMID: 40138447 Free PMC article.
-
MicroRNA-124-3p suppresses cell migration and invasion by targeting ITGA3 signaling in bladder cancer.Cancer Biomark. 2019;24(2):159-172. doi: 10.3233/CBM-182000. Cancer Biomark. 2019. PMID: 30614803
-
Zinc-Dependent Regulation of ZEB1 and YAP1 Coactivation Promotes Epithelial-Mesenchymal Transition Plasticity and Metastasis in Pancreatic Cancer.Gastroenterology. 2021 Apr;160(5):1771-1783.e1. doi: 10.1053/j.gastro.2020.12.077. Epub 2021 Jan 6. Gastroenterology. 2021. PMID: 33421513 Free PMC article.
-
LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.Cancer Res. 2021 Nov 15;81(22):5678-5691. doi: 10.1158/0008-5472.CAN-21-0281. Epub 2021 Sep 30. Cancer Res. 2021. PMID: 34593522
Cited by
-
Reprogramming of glucose metabolism in pancreatic cancer: mechanisms, implications, and therapeutic perspectives.Front Immunol. 2025 Jun 24;16:1586959. doi: 10.3389/fimmu.2025.1586959. eCollection 2025. Front Immunol. 2025. PMID: 40630951 Free PMC article. Review.
-
Suppression of FOXO1 activity by SIRT1-mediated deacetylation weakening the intratumoral androgen autocrine function in glioblastoma.Cancer Gene Ther. 2025 Mar;32(3):343-354. doi: 10.1038/s41417-025-00880-1. Epub 2025 Mar 12. Cancer Gene Ther. 2025. PMID: 40075208 Free PMC article.
-
Serine-Driven Metabolic Plasticity Drives Adaptive Resilience in Pancreatic Cancer Cells.Antioxidants (Basel). 2025 Jul 7;14(7):833. doi: 10.3390/antiox14070833. Antioxidants (Basel). 2025. PMID: 40722937 Free PMC article.
-
Machine learning-based construction of a programmed cell death-related model reveals prognosis and immune infiltration in pancreatic adenocarcinoma patients.Sci Rep. 2025 Jul 11;15(1):25156. doi: 10.1038/s41598-025-10847-9. Sci Rep. 2025. PMID: 40646168 Free PMC article.
-
Targeting Siglec-10/α3β1 Integrin Interactions Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer.bioRxiv [Preprint]. 2025 Jul 19:2025.05.06.652455. doi: 10.1101/2025.05.06.652455. bioRxiv. 2025. PMID: 40654843 Free PMC article. Preprint.
References
-
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33. - PubMed
-
- Huang J, Lok V, Ngai CH, Zhang L, Yuan J, Lao XQ, et al. Worldwide burden of, risk factors for, and trends in pancreatic cancer. Gastroenterology. 2021;160:744–54. - PubMed
-
- Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32. - PubMed
-
- Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395:2008–20. - PubMed
-
- Yu S, Zhang C, Xie KP. Therapeutic resistance of pancreatic cancer: Roadmap to its reversal. Biochim Biophys Acta Rev Cancer. 2021;1875:188461. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous